Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyperAcute-Prostate Vaccine in Hormone Refractory Prostate Cancer
NCT00105053Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Mar 2005
- Primary completion
- Sep 2007
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of algenpantucel-P in prostate cancer (PCa), sponsored by Lumos Pharma, Inc.. Started Mar 2005; status: completed.
02
Drugs
algenpantucel-P
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00105053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00105053.